Use of the Cereprotex prior to and after the CABG procedures to substantially reduce or eliminate the effects of neuro-impairment.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.

The first stages of this project involve progressing a new neuroprotection indication for the prototype Cereprotex drug as well as a limited rational derivatization of this Cereprotex compound with natural substituents (having minimal toxicity) known for their neuroprotective properties to increase the chances to find appropriate second-third generation lead compounds. These substituents are hypothesized to complement the neuroprotective effect of the parent molecule by adding additional elements (i.e. anti-oxidative, etc.) which have been postulated to decrease neural impairment. These compounds will be compared to the parent prototype compound as a result of screening them with the relevant animal models. One to two lead compounds will be chosen to continue towards preclinical studies within the course of a 2 year time frame. While the initial focus will be the CABG effects, Cereprotec Inc. team believes that it’s Cereprotex formula and derivatives will show substantial improvement in treating TBI (Traumatic Brain Injury), Stroke, Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other neurological diseases.